Gedunin

Pricing Availability   Qty
Description: Hsp90 inhibitor; exhibits anticancer and antimalarial activity
Chemical Name: (1S,3aS,4aR,4bS,5R,6aR,10aR,10bR,12aS)-5-(Acetyloxy)-1-(3-furanyl)-1,5,6,6a,7,10a,10b,11,12,12a,decahydro-4b,7,7,10a,12a,-pentamethyloxireno[c]phenanthro[1,2-d]pyran-3,8(3aH,4bH)-dione
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews (1)
Literature (2)

Biological Activity for Gedunin

Gedunin is a naturally occurring Hsp90 inhibitor. Induces Hsp90-dependent client protein degradation and displays antiproliferative activity in vitro (IC50 values are 3.22, 8.84 and 16.8 μM in SKBr3, MCF-7 and CaCo-2 cancer cell lines respectively). Decreases ovarian cancer cell proliferation in vitro and may enhance cisplatin-induced reduction in proliferation (CAT.No 3387). Also exhibits antimalarial activity against Plasmodium falciparum (IC50 values are 0.14 and 3.1 μM in parasite development and [3H]-hypoxanthine uptake assays respectively).

Technical Data for Gedunin

M. Wt 482.57
Formula C28H34O7
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 2753-30-2
PubChem ID 12004512
InChI Key YJXDGWUNRYLINJ-BHAPSIHVSA-N
Smiles O=C4[C@@H]6[C@]3(O6)[C@]2(C)[C@H](OC(C)=O)C[C@@]1([H])C(C)(C)C(C=C[C@@](C)1[C@]([H])2CC[C@](C)3[C@H]([C@]5=COC=C5)O4)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Gedunin

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 48.26 100
ethanol 4.83 10 with gentle warming

Preparing Stock Solutions for Gedunin

The following data is based on the product molecular weight 482.57. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.07 mL 10.36 mL 20.72 mL
5 mM 0.41 mL 2.07 mL 4.14 mL
10 mM 0.21 mL 1.04 mL 2.07 mL
50 mM 0.04 mL 0.21 mL 0.41 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for Gedunin

Certificate of Analysis / Product Datasheet
Select another batch:

References for Gedunin

References are publications that support the biological activity of the product.

Uddin et al (2007) Gedunin, a limonoid from Xylocarpus granatum, inhibits the growth of CaCo-2 colon cancer cell line in vitro. Phytother.Res. 21 757 PMID: 17450509

Brandt et al (2008) Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J.Med.Chem. 51 6495 PMID: 18816111

Lee et al (2008) Antimalarial activity of anthothecol derived from Khaya anthotheca (Meliaceae). Phytomedicine 15 533 PMID: 17913482

Kamath et al (2009) Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer. 19 1564 PMID: 19955938


If you know of a relevant reference for Gedunin, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Hsp90 Inhibitors

Keywords: Gedunin, Gedunin supplier, Hsp90, inhibitors, inhibits, anticancer, antimalarial, activity, Heat, Shock, Protein, 90, Plasmodium, falciparum, Antimalarials, 3387, Tocris Bioscience

2 Citations for Gedunin

Citations are publications that use Tocris products. Selected citations for Gedunin include:

Rizk et al (2015) Optimization of a Fluorescence-Based Assay for Large-Scale Drug Screening against Babesia and Theileria Parasites. PLoS One 10 e0125276 PMID: 25915529

Yadav et al (2010) Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) 88 1243 PMID: 20798912


Do you know of a great paper that uses Gedunin from Tocris? Please let us know.

Reviews for Gedunin

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Gedunin?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Gedunin used to demonstrate anti-proliferative activity.
By Rutsha L Phillips on 12/14/2019
Species: Human

Gedunin used to demonstrate anti-proliferative activity against prostate cancer cell line. The depletion of cellular levels of Hsp90-dependent client proteins was scrutinised.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cell Cycle and DNA Damage Research Product Guide

Cell Cycle and DNA Damage Research Product Guide

This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:

  • Cell Cycle and Mitosis
  • DNA Damage Repair
  • Targeted Protein Degradation
  • Ubiquitin Proteasome Pathway
  • Chemotherapy Targets
Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.